CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia

Leukemia

Volumn 28, Issue 3, 2014, Pages 566-576

  Brault, L ^a   Rovo A ^b   Decker, S ^c   Dierks, C ^c   Tzankov, A ^d   Schwaller, J ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

AML; CXCR4; Homing; Resistance; Retention; Serine339

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; MUTANT PROTEIN; PLERIXAFOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER RESISTANCE; CELL ADHESION; CELL MOTILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CELL ADHESION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTORS, CXCR4; SERINE;

EID: 84895785740     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.201     Document Type: Article

References (41)

1. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845-848.
2. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004; 64: 2817-2824.
3. Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 2009; 4: 96-103.
4. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768: 952-963.
5. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-557.
6. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786-791.
7. Voermans C, van Heese WP, de Jong I, Gerritsen WR, van Der Schoot CE. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 2002; 16: 650-657.
8. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-Arrestins in receptor signaling and desensitization. J Biol Chem 1998; 273: 18677-18680.
9. Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010; 341: 173-191.
10. Guinamard R, Signoret N, Ishiai M, Marsh M, Kurosaki T, Ravetch JV. B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J Exp Med 1999; 189: 1461-1466.
11. Minina S, Reichman-Fried M, Raz E. Control of receptor internalization, signaling level, and precise arrival at the target in guided cell migration. Curr Biol 2007; 17: 1164-1172.
12. Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-Terminal tail that mediate receptor internalization. J Biol Chem 1999; 274: 31076-31086.
13. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010; 285: 7805-7817.
14. Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S et al. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009; 206: 1957-1970.
15. Brault L, Menter T, Obermann EC, Knapp S, Thommen S, Schwaller J et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer 2012; 107: 491-500.
16. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116.
17. Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V et al. Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 2010; 24: 601-612.
18. Shaposhnikov VL. [Distribution of the bone marrow cells in the skeleton of mice]. Biull Eksp Biol Med 1979; 87: 483-485.
19. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z et al. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 2011; 25: 1739-1750.
20. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
21. Obermann EC, Arber C, Jotterand M, Tichelli A, Hirschmann P, Tzankov A. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia. Ann Hematol 2010; 89: 663-669.
22. Tzankov A, Strasser U, Dirnhofer S, Menter T, Arber C, Jotterand M et al. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival. Ann Hematol 2011; 90: 901-909.
23. Hicke L, Zanolari B, Riezman H. Cytoplasmic tail phosphorylation of the alpha-factor receptor is required for its ubiquitination and internalization. J Cell Biol 1998; 141: 349-358.
24. Pitcher C, Honing S, Fingerhut A, Bowers K, Marsh M. Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation. Mol Biol Cell 1999; 10: 677-691.
25. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34þ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523-4530.
26. Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Nye KE et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 2003; 101: 399-406.
27. Rosu-Myles M, Gallacher L, Murdoch B, Hess DA, Keeney M, Kelvin D et al. The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression. Proc Natl Acad Sci USA 2000; 97: 14626-14631.
28. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: Ra81.
29. Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F et al. Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One 2012; 7: E37203.
30. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 2007; 109: 1152-1156.
31. Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009; 33: 764-768.
32. Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004; 22: 188-201.
33. Woerner BM, Warrington NM, Kung AL, Perry A, Rubin JB. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 2005; 65: 11392-11399.
34. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM et al. Phosphorylated CXCR4 is associated with poor survival in adults with B-Acute lymphoblastic leukemia. Cancer 2011; 117: 31.
35. Kawai T, Choi U, Whiting-Theobald NL, Linton GF, Brenner S, Sechler JM et al. Enhanced function with decreased internalization of carboxy-Terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 2005; 33: 460-468.
36. Delgado-Martin C, Escribano C, Pablos JL, Riol-Blanco L, Rodriguez-Fernandez JL. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. J Biol Chem 2011; 286: 37222-37236.
37. Ryu CH, Park SA, Kim SM, Lim JY, Jeong CH, Jun JA et al. Migration of human umbilical cord blood mesenchymal stem cells mediated by stromal cell-derived factor-1/CXCR4 axis via Akt, ERK, and p38 signal transduction pathways. Biochem Biophys Res Commun 2010; 398: 105-110.
38. Kawai T, Choi U, Cardwell L, DeRavin SS, Naumann N, Whiting-Theobald NL et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-Terminus-Truncated CXCR4. Blood 2007; 109: 78-84.
39. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 2013; 123: 2395-2407.
40. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
41. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924..